Loading clinical trials...
Loading clinical trials...
The objectives of this phase Ib study are to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics and immunogenic profiles of B001 in subjects with aquaporin-4 antibody (AQP4-IgG) positiv...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
NCT05004493 · Antibody-mediated Rejection, NMO Spectrum Disorder, and more
NCT05154370 · Multiple Sclerosis, NMO Spectrum Disorder, and more
NCT05403138 · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, and more
NCT05154734 · NMO Spectrum Disorder
NCT02028884 · Neuromyelitis Optica (NMO), NMO Spectrum Disorder (NMOSD)
Beijing Tiantan Hospital Capital Medical University
Beijing, Beijing Municipality
First Hospital of Shanxi Medical University
Taiyuan, Shanxi
Tangdu hospital,fourth military medical university
Xi’an, Shanxi
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions